APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer Arsela Prelaj, Leonardo Provenzano, Vanja Miskovic, Monica Ganzinelli, Laura Mazzeo, Maria Gemelli, Cecilia Silvestri, Andrea Spagnoletti, Rebecca Romanò, Marta Brambilla, Mario Occhipinti, Teresa Beninato, Paolo Ambrosini, Elisa Sottotetti, Margherita Favali, Aleksandra Zec, Alberto Ferrarin, Giulia Corrao, Marco Meazza Prina, Margherita Ruggirello, Moreno Bruno Marino, Andra Diana Dumitrascu, Rosa Maria Di Mauro, Claudia Giani, Chiara Cavalli, Roberta Serino, Chiara Catania, Antonella Panzardi, Giulio Metro, Chiara Bennati, Roberto Ferrara, Marianna Macerelli, Alberto Servetto, Maria Silvia Cona, Nicla La Verde, Luca Toschi, Paolo Baili, Federica Corso, Emanuela Zito, Saverio Cinieri, Rossana Berardi, Giovanni Scoazec, Alessandro Inno, Stefania Gori, Salvatore Pisconti, Federica Buzzacchino, Matteo Brighenti, Federica Biello, Alfredo Tartarone, Giancarlo Pruneri, Antonino Belfiore, Luca Agnelli, Alessandro Guidi, Luca Invernizzi, Noemi Salmistraro, Andrea Riccardo Filippi, Piergiorgio Solli, Giulia Galli, Daniele Lorenzini, Elio Gregory Pizzutilo, Filippo De Braud, Alessandra Pedrocchi, Francesco Trovò, Carlo Genova, Carminia Maria Della Corte, Giuseppe Viscardi, Marina Chiara Garassino, Alessio Cortellini, Emanuele Mingo, Marco Russano, Diego Signorelli, Claudia Proto, Andrea Vingiani, Sabina Sangaletti, Giuseppe Lo Russo, , Giorgia Di Liberti, Claudia Agosta, Ghazal Farhikhteh, Daniela Miliziano, Giorgia Corbo, Beshoy Guirges, Cristina Licciardello, Lorenzo Antonuzzo, Francesco Verderame, Giulia Barletta, Gianpaolo Spinelli, Rita Chiari, Rita Emili, Federica Bertolini, Grisanti Salvatore, Emanuele Vita, Chiara Bonalume, Michele Aieta, Luigi Lacriola, Michele Borraccino, Claudia Bareggi, Fabrizio Citarella, Giovanni Apolone, Silvia Taverna, Antonio Lugini, Cesare Fattoi, Alfonso Marchianò, Alessandro Leonetti Npj Precision Oncology, 2026 Identifying predictive and resistance biomarkers remains one of the most relevant unmet needs in clinical cancer research. Artificial Intelligence (AI) represents a powerful tool to develop predictive algorithms tailored to individual patients. Thanks to its ability to process large quantities of heterogeneous, patient-level information, the AI-based approach is progressively fostering the growth of a data-driven paradigm to complement traditional, hypothesis-driven clinical research. However, the development of reliable AI models requires access to large, high-quality, and continuously updated datasets. Despite this necessity, no infrastructure currently exists to enable federated, multi-omic, standardized, prospective, and large-scale collection and analysis of real-world clinical and biological data in the context of lung cancer. We established the APOLLO11 consortium, a distributed, nationwide, updated Italian lung cancer network designed to build a decentralized, long-term, population-based, real-world data repository and a multilevel biobank, locally stored and centrally annotated. This strategy seeks to lay the foundation for the clinical implementation of data-driven research, ultimately advancing precision oncology.
Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review Sabrina Chiloiro, Simone Antonio De Sanctis, Bianca Parente, Antonella Giampietro, Tatiana D’Angelo, Eleonora Palluzzi, Ernesto Rossi, Laura Vertechy, Emanuele Vita, Ida Paris, Claudia Marchetti, Laura De Marinis, Antonio Bianchi, Roberto Iaconelli, Giovanni Schinzari, Giampaolo Tortora, Anna Fagotti, Alfredo Pontecorvi Reviews in Endocrine and Metabolic Disorders, 2026 Immunotherapy-induced primary adrenal insufficiency (Ir-PAI) is a rare complication of immune checkpoint inhibitors (ICI). The clinical presentation is typically heterogeneous, with complex clinical pictures that may overlap with those of other endocrinopathies. Therefore, Ir-PAI may represent a life-threatening condition, with a possible subtle or acute onset, a high risk of electrolyte disorders, and hemodynamic instability. The management of Ir-PAI in cancer patients treated with ICIs requires a multidisciplinary management, involving at least oncologists and endocrinologists, to reach an early diagnosis, to safely manage patients, and to guarantee higher compliance and adherence to ICI treatment. In this study, we aimed to systematically examine cases of Ir-PAI reported in the literature and to describe our clinical experience. A total of 12 patients with Ir-PAI were collected from a systematic literature review, including cases reported from January 2011 to June 2025. Four patients were instead diagnosed at our Institution. Therefore, the evaluation of all 16 patients with Ir-PAIs identified 11 males (68.8%). Median age at PAI onset was 65 years (IQR: 18). The most common symptom at the occurrence of Ir-PAIs was asthenia/fatigue in 13 patients (81.3%). Ir-PAIs occurred more frequently in patients treated with anti-PD-1 mAbs (9 cases, 56.3%), and the most prevalent primary tumors associated with Ir-PAIs were renal cell carcinomas in four patients (25%). Other concomitant endocrine toxicities in patients with Ir-PAIs were thyroid dysfunctions in 8 patients (50%), and hypogonadism in 2 patients (12.5%). Our systematic review shows that Ir-PAI is a rare but clinically relevant toxicity of ICIs.
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study Alessandro Leonetti, Vanessa Callegari, Fabiana Perrone, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Giulia Barletta, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Sara Oresti, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Alessandro Russo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Francesco Paoloni, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Corrado Ficorella, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Matteo Puntoni, Marcello Tiseo Tumori, 2026 Introduction Chemo–immunotherapy is the standard frontline treatment of advanced non–squamous non–small cell lung cancer (nsq–NSCLC). Among oncogenic drivers, KRAS mutation accounts for approximately 25% of lung adenocarcinomas, with p.G12C being the most common variant. This study assessed clinical features and survival outcomes according to KRAS mutation in a real–life population of nsq–NSCLC patients treated with first–line platinum–pemetrexed–pembrolizumab. Methods This is a retrospective–prospective study including patients with nsq–NSCLC who received first–line platinum–pemetrexed–pembrolizumab from 4 September 2018 in 33 Italian Centers. Results Among the 765 patients included in this analysis, 121 (15.8%) had KRAS p.G12C mutation, 201 (26.3%) KRAS non–p.G12C mutation and 443 (57.9%) KRAS WT. KRAS –mutated patients had more frequently a history of smoking (90.6% vs 84.1%, p=0.012) and bone metastases (44.1% vs 35.9%; p=0.022) compared to KRAS WT. Median Overall Survival (OS) was similar between KRAS –mutated and KRAS WT patients (16.7 vs 18.2 months; adjusted Hazard Ratio [HR] 1.19, 95% Confidence Interval [CI] 0.95–1.50, p=0.132). No difference in OS was found between KRAS p.G12C and KRAS non–p.G12C (15.9 vs 17.0 months, HR 0.93, 95% CI: 0.66–1.31, p=0.676). Median progression–free survival was significantly shorter in KRAS –mutated compared to KRAS WT patients (8.8 vs 10.8 months; adjusted HR 1.29, 95% CI 1.04–1.59, p=0.018), with no differences between KRAS p.G12C and KRAS non–p.G12C (8.8 vs 8.8 months, HR 0.95, 95% CI: 0.70–1.30, p=0.756). Conclusions KRAS mutation showed a potential negative predictive role in advanced nsq–NSCLC treated with first–line chemo–immunotherapy. The impact of co–mutations and post–progression outcomes warrants further investigation.
Real-life management of stage III non-small cell lung cancer patients in Italy: the BE-PACIFIC observational study Paolo Bironzo, Alessandro Morabito, Sonia Silipigni, Vincenzo Adamo, Enrica Capelletto, Sabrina Rossi, Marcello Tiseo, Michele Montrone, Ivan Facilissimo, Gianpiero Romano, Luna Chiara Masini, Giovanni Luca Ceresoli, Cesare Gridelli, Antonio Lugini, Sara Pilotto, Pierosandro Tagliaferri, Emilio Bria, Diego Cortinovis, Erika Rijavec, Paolo Borghetti, Matteo Brighenti, Anna Maria Carta, Libero Ciuffreda, Raffaele Giusti, Marianna Macerelli, Francesco Verderame, Francesca Zanelli, Rossana Berardi, Vanesa Gregorc, Concetta Sergi, Emanuela Vattemi, Roberto Ferrara, Pier Luigi Piovano, Lorenzo Livi, Gloria Borra, Stefania Gori, Michele Aieta, Alessandro Bertolini, Fabiana Letizia Cecere, Giulia Pasello, Danilo Rocco, Giuseppe Lo Certo, Livia Marrone, Lucia Simoni, Barbara Roncari, Silvia Novello, Sara Ramella, Rossana Critelli, Elisa Cibrario Rocchietti, Simona Carnio, Francesco Passiglia, Valentina Bertaglia, Emanuela Olmetto, Carlo Greco, Edy Ippolito, Barbara Papi, Pierluigi Falco, Alessandra Ferro, Alessandro Dal Maso, Giulia Doria, Stefano Frega, Annalisa Nardone, Patrizia Petrillo, Gianluca Cuomo, Maria Bonomi, Valeria Nava, Marta Magni, Serena Verna, Claudia Proto, Rosa Maria Di Mauro, Giulia Galli, Giuseppe Lo Russo, Clara Fugazza, Maria Grazia Viganò, Chiara Lazzari, Paolo Maione, Maria Luisa Barzelloni, Angelo Cirocco, Fiorella Lombardo, Lorenzo Belluomini, Jessica Insolda, Alessandra Marabese, Roberta Camisa, Alessandro Leonetti, Sebastiano Buti, Simona Damiano, Giuliano Palumbo, Alfredo Tartarone, Vittoria Lapadula, Emanuela Zifarone, Stefania Crivellari, Silvia Zai, Fabio Giacchero, Chiara Bonfadini, Agostino Ponzetti, Enrica Milanesi, Tiziana Scirelli, Silvana Leo, Valeria Saracino, Amelia Vantaggiato, Loretta Paolelli, Emma Maria Saba, Daniela Guerzoni, Jessica Imbrescia, Nuzhat Noreen, Giacomo Allegrini, Irene Stasi, Chiara Finale, Luigi Coltelli, Gianna Musettini, Samanta Cupini, Azzurra Farnesi, Veronica Franchina, Alessandro Russo, Graziella Rizzo, Antonino Scimone, Tindara Franchina, Marco Filetti, Maria Bonomi, Nicoletta Nanni, Sabrina Vari, Consuelo D'Ambrosio, Elisabetta Bozzoli, Elisa Sala, Giovanna Finocchiaro, Luca Toschi, Lucia Damicis, Arianna Marinello, Lucia Ferraro, Elisabetta Menatti, Panagiotis Deligiannis, Oriana Commendatore, Francesco Avola, Maria Celeste Pirozzoli, Maria Anna Teberino, Emanuele Vita, Alessio Stefani, Michela Burattini, Zelmira Ballatore, Alessandra Lucarelli, Francesca Morgese, Filippo Merloni, Candida Bonelli, Claudia Bareggi, Francesca Barbìn, Alessandro Follador, Simona Rizzato, Ciro Rossetto, Barbara Bonifacio, Carla Corvaja, Giada Targato, Alessandro Inno, Fabiana Marchetti, Vincenzo Picece, Matilde Fiorini, Mariangela Lopreiato, Francesca Spinnato, Anna Mangiaracina, Erika Lo Iacono, Enrico Bronte, Vieri Scotti, Matteo Mariotti, Lucia Pia Ciccone, Damiano Dei, Marco Banini, Benedetta Agresti, Victoria Lorenzetti, Virginia Votino, Federica Biello, Paola Maggiora, Silvia Genestroni, Carmen Branni Cancer Treatment and Research Communications, 2026 BACKGROUND: Stage III non-small cell lung cancer (NSCLC) includes a heterogeneous group of patients with diverse disease presentation, biological portrait, and prognosis. Optimal management requires tailored approaches and multimodal strategies through a multidisciplinary team (MDT) decision-making process. The BE-PACIFIC study primarily aimed at describing treatment strategies of stage III NSCLC according to the Italian standard clinical practice, diagnostic work-up and survival outcomes during observation. PATIENTS AND METHODS: The BE-PACIFIC is an observational multicentre retrospective and prospective cohort study, involving both primary data collection and secondary use of data. Adult patients with confirmed diagnosis of stage III NSCLC were included by 40 sites and followed up for 12 months after diagnosis. RESULTS: percentiles) duration of the diagnostic process was 30.4 (21.0-60.9) days. MDT was involved in treatment plan definition of 88.7% (n/N=260/293) of patients. Sixty (20.3%) patients had tumour resection, mostly associated with neoadjuvant (n=26, 43.3%) or adjuvant (n=22, 36.7%) treatment alone. Chemoradiation was used in 165 of 236 (69.9%) non-resected patients, followed by durvalumab in 80 cases (48.5%). CONCLUSIONS: MDT was largely involved in stage III NSCLC management, with at least 75% of patients completing the diagnostic process within 2 months. Consolidation durvalumab was used in half of non-resected patients treated with chemoradiation, with favourable retention rates and response, consistently with the PACIFIC trial findings.
Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib E. Vita, A. Scala, A. Vitale, L. Mastrantoni, J. Evangelista, F. D’Auria, A. Stefani, F. Monaca, J. Russo, G. Horn, P. Troisi, A. Cosmai, S. Polidori, M. Di Salvatore, E. De Paolis, A. Minucci, C. Nero, R. Trisolini, A. Cancellieri, G. Scambia, G. Tortora, E. Bria ESMO Open, 2025 BACKGROUND: Fusion events involving neuregulin 1 (NRG1), a member of the pan-HER pathway, have been highlighted as a potential therapeutic target; however, little is known about the epidemiological distribution and the prognostic value of NRG1 variants in large real-world datasets. MATERIALS AND METHODS: Data from 878 patients with newly diagnosed advanced non-small-cell lung cancer who had undergone DNA- and RNA-based comprehensive genomic profiling from January 2022 to October 2024 were retrospectively collected in the context of the FPG500 program (interventional monocentric prospective study, NCT06020625). RESULTS: Comprehensive genomic profiling analysis reported NRG1 variants of uncertain significance (VUSes) in 70 samples (8.0%), including 41 deletions (58.6%), 21 sequence variants (33.0%), 2 double genetic hits (2.8%) and 2 amplifications (2.8%). Forty NRG1-mutant patients (57.1%) presented one main actionable genomic alteration, particularly EGFR, HER2 and KRAS mutation. NRG1 VUSes occurred along with genes regulating the RTK/KRAS pathway in 59 samples (84%), the TP53 pathway in 47 samples (67%) and the PI3K pathway in 27 samples (39%). In multivariate analysis carried out in a retrospective cohort of EGFR M+ (del19/L858R) patients treated with osimertinib, EGFRM+/NRG1wt patients showed significantly longer progression-free survival (PFS) and overall survival (OS) compared with EGFRM+/NRG1 M+ patients {PFS 26.07 versus 12.07 months [hazard ratio (HR) 0.34, 95% confidence interval 0.12-0.95, P = 0.0015]; OS 34.06 versus 20.45 months (HR 0.45, 95% confidence interval 0.22-0.93, P = 0.0230)}. CONCLUSIONS: Although retrospective, these data support the hypothesis that NRG1 VUSes are frequently associated with poor prognosis and other oncogene alterations. In EGFR M+ patients treated with osimertinib, concurrent NRG1 alterations were an independent poor prognostic factor for both PFS and OS, raising the need of further validation.
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis Federico Monaca, Igor Gomez-Randulfe, Gerard Walls, Ornella Cantale, Ana Parreira, Sara Polidori, Mariantonietta Di Salvatore, Vito Longo, Domenico Galetta, Emanuele Vita, Antonella Martino, Maria Antonietta Gambacorta, Luca Boldrini, Yvonne Summers, Giampaolo Tortora, Fiona Blackhall, Silvia Novello, Clara Chan, Emilio Bria, Corinne Faivre-Finn, Raffaele Califano European Journal of Cancer, 2025
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report Antonio Vitale, Emanuele Vita, Alessio Stefani, Alessandra Cancellieri, Filippo Lococo, Giampaolo Tortora, Emilio Bria Oncologist, 2025 Precision oncology has transformed non-small cell lung cancer (NSCLC) treatment by tailoring therapies to the genomic profile of the disease, significantly improving clinical outcomes. However, acquired resistance to molecularly targeted therapies remains a major challenge. This report details a 69-year-old woman with KRAS G12C-mutant metastatic NSCLC who developed resistance to sotorasib, a KRAS G12C inhibitor. Initially responding to the standard dose of 960 mg, the patient required a dose reduction to 480 mg due to liver toxicity. After 20 months, oligoprogression occurred, managed through surgical resection. Molecular analysis of the resected tissue identified KRAS amplification as a resistance mechanism. Following disease progression, re-escalation of sotorasib to 960 mg led to renewed tumor response without additional toxicity. This case highlights dose re-escalation as a potential strategy to address resistance in selected patients and underscores the critical role of molecular profiling and personalized approaches in optimizing targeted NSCLC treatments.
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer Emanuele Vita, Federico Monaca, Luca Mastrantoni, Geny Piro, Giacomo Moretti, Ileana Sparagna, Alessio Stefani, Antonio Vitale, Giovanni Trovato, Mariantonietta Di Salvatore, Maurizio Sanguinetti, Andrea Urbani, Luca Richeldi, Carmine Carbone, Emilio Bria, Giampaolo Tortora Vaccines, 2025 Background: As COVID-19 has become an epidemic, we conducted an open-label study aimed to identify immunogenicity and reactogenicity of boosters of the BNT162b2 vaccine in a real-world cohort of long-survivor metastatic lung cancer patients (LS-mLC pts). Methods and Analysis: According to the timing of the booster dose (BD) and SARS-CoV-2 infection (Cov-I) during anticancer treatment (ACT), between October 2021 and February 2022, we prospectively enrolled 166 cancer patients into five parallel cohorts. The primary endpoints were seroprevalence of IgG Anti-spike-RBD (anti-S IgG) at two pre-defined timepoints (T1: +30–90 days after BD; T2: +6 months +/− 4 weeks after BD). As an exploratory endpoint, we compared the median pre-vaccination value of four cytokines (IL-6, IL-2R, TNF-α, IL-10) with post-BD values in immunotherapy-treated pts (IO-pts). Results: The anti-S IgG seropositivity rate was 100% at T1 and 98.8% at T2. After 6 months, hybrid immunisation was associated with a higher median anti-S IgG titre compared to vaccine-alone-induced seroconversion (p < 0.0001). In uninfected pts, the median anti-S IgG titre was significantly lower in IO-pts compared to non-IO-pts (p = 0.02); no difference was found when comparing myelosuppressive or not ACT. Among the 68 IO-pts, 5 pts (7.3%) showed a significant increase (≥1.5 fold) of at least two cytokines in post-BD samples, without reporting ir-AEs. Conclusions: Boosters of the COVID-19 mRNA vaccine were effective and safe. In IO-pts without recent Cov-I, additional BDs should be considered to prolong serological immunity.
PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance Sara Pilotto, Lorenzo Belluomini, Federico Monaca, Michele Simbolo, Antonio Agostini, Andrea Mafficini, Stela Golovco, Isabella Sperduti, Emanuele Vita, Alessio Stefani, Carmine Carbone, Geny Piro, Miriam Grazia Ferrara, Filippo Lococo, Vienna Ludovini, Rita Chiari, Silvia Novello, Vincenzo Corbo, Michele Milella, Aldo Scarpa, Giampaolo Tortora, Emilio Bria Therapeutic Advances in Medical Oncology, 2025
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study Ilaria Trestini, Lorenzo Belluomini, Alessandra Dodi, Marco Sposito, Alberto Caldart, Dzenete Kadrija, Luca Pasqualin, Silvia Teresa Riva, Ilaria Mariangela Scaglione, Daniela Tregnago, Alice Avancini, Jessica Insolda, Linda Confortini, Miriam Casali, Jessica Menis, Emanuele Vita, Marco Cintoni, Marco Todesco, Gianluca Milanese, Isabella Sperduti, Mirko D'Onofrio, Marco Infante, Marcello Tiseo, Maria Cristina Mele, Giampaolo Tortora, Michele Milella, Emilio Bria, Sara Pilotto Journal of Cachexia Sarcopenia and Muscle, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed Alessandro Leonetti, Fabiana Perrone, Matteo Puntoni, Giuseppe Maglietta, Paola Bordi, Emilio Bria, Emanuele Vita, Francesco Gelsomino, Andrea De Giglio, Alain Gelibter, Marco Siringo, Francesca Mazzoni, Enrico Caliman, Carlo Genova, Federica Bertolini, Giorgia Guaitoli, Francesco Passiglia, Marco Donatello Delcuratolo, Michele Montrone, Giulio Cerea, Giulia Pasello, Elisa Roca, Lorenzo Belluomini, Fabiana Letizia Cecere, Annalisa Guida, Anna Manzo, Vincenzo Adamo, Francesca Rastelli, Alessandra Bulotta, Fabrizio Citarella, Luca Toschi, Federica Zoratto, Diego Luigi Cortinovis, Rossana Berardi, Alessandro Follador, Annamaria Carta, Andrea Camerini, Flavio Salerno, Rosa Rita Silva, Editta Baldini, Alessio Cortellini, Matteo Brighenti, Matteo Santoni, Francesco Malorgio, Caterina Caminiti, Marcello Tiseo European Journal of Cancer, 2024
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research Arsela Prelaj, Monica Ganzinelli, Leonardo Provenzano, Laura Mazzeo, Giuseppe Viscardi, Giulio Metro, Giulia Galli, Francesco Agustoni, Carminia Maria Della Corte, Andrea Spagnoletti, Claudia Giani, Roberto Ferrara, Claudia Proto, Marta Brambilla, Andra Diana Dumitrascu, Alessandro Inno, Diego Signorelli, Elio Gregory Pizzutilo, Matteo Brighenti, Federica Biello, Chiara Bennati, Luca Toschi, Marco Russano, Alessio Cortellini, Chiara Catania, Federica Bertolini, Rossana Berardi, Luca Cantini, Federica Pecci, Marianna Macerelli, Rita Emili, Claudia Bareggi, Francesco Verderame, Antonio Lugini, Salvatore Pisconti, Federica Buzzacchino, Michele Aieta, Alfredo Tartarone, Gianpaolo Spinelli, Emanuele Vita, Salvatore Grisanti, Francesco Trovò, Pietro Auletta, Daniele Lorenzini, Luca Agnelli, Sabina Sangaletti, Francesca Mazzoni, Giuseppina Calareso, Margherita Ruggirello, Gabriella Francesca Greco, Raffaella Vigorito, Mario Occhipinti, Sara Manglaviti, Teresa Beninato, Rita Leporati, Paolo Ambrosini, Roberta Serino, Cecilia Silvestri, Emanuela Zito, Alessandra Chiara Laura Pedrocchi, Vanja Miskovic, Filippo de Braud, Giancarlo Pruneri, Giuseppe Lo Russo, Carlo Genova, Andrea Vingiani Clinical Lung Cancer, 2024
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study Filippo Lococo, Luca Boldrini, Charles-Davies Diepriye, Jessica Evangelista, Camilla Nero, Sara Flamini, Angelo Minucci, Elisa De Paolis, Emanuele Vita, Alfredo Cesario, Salvatore Annunziata, Maria Lucia Calcagni, Marco Chiappetta, Alessandra Cancellieri, Anna Rita Larici, Giuseppe Cicchetti, Esther G.C. Troost, Ádány Róza, Núria Farré, Ece Öztürk, Dominique Van Doorne, Fausto Leoncini, Andrea Urbani, Rocco Trisolini, Emilio Bria, Alessandro Giordano, Guido Rindi, Evis Sala, Giampaolo Tortora, Vincenzo Valentini, Stefania Boccia, Stefano Margaritora, Giovanni Scambia BMC Cancer, 2023
Correction: Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN study (BMC Cancer, (2023), 23, 1, (540), 10.1186/s12885-023-10997-x) Filippo Lococo, Luca Boldrini, Charles-Davies Diepriye, Jessica Evangelista, Camilla Nero, Sara Flamini, Angelo Minucci, Elisa De Paolis, Emanuele Vita, Alfredo Cesario, Salvatore Annunziata, Maria Lucia Calcagni, Marco Chiappetta, Alessandra Cancellieri, Anna Rita Larici, Giuseppe Cicchetti, Esther G. C. Troost, Róza Ádány, Núria Farré, Ece Öztürk, Dominique Van Doorne, Fausto Leoncini, Andrea Urbani, Rocco Trisolini, Emilio Bria, Alessandro Giordano, Guido Rindi, Evis Sala, Giampaolo Tortora, Vincenzo Valentini, Stefania Boccia, Stefano Margaritora, Giovanni Scambia BMC Cancer, 2023
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study Melissa Bersanelli, Sebastiano Buti, Diana Giannarelli, Alessandro Leonetti, Alessio Cortellini, Giuseppe Lo Russo, Diego Signorelli, Luca Toschi, Michele Milella, Sara Pilotto, Emilio Bria, Claudia Proto, Arianna Marinello, Giovanni Randon, Sabrina Rossi, Emanuele Vita, Giulia Sartori, Ettore D’Argento, Eva Qako, Elisa Giaiacopi, Laura Ghilardi, Anna Cecilia Bettini, Elena Rapacchi, Francesca Mazzoni, Daniele Lavacchi, Vieri Scotti, Lucia Pia Ciccone, Michele De Tursi, Pietro Di Marino, Daniele Santini, Marco Russano, Paola Bordi, Massimo Di Maio, Marco Audisio, Marco Filetti, Raffaele Giusti, Rossana Berardi, Ilaria Fiordoliva, Giulio Cerea, Elio Gregory Pizzutilo, Alessandra Bearz, Elisa De Carlo, Fabiana Cecere, Davide Renna, Roberta Camisa, Giuseppe Caruso, Corrado Ficorella, Giuseppe Luigi Banna, Diego Cortinovis, Matteo Brighenti, Marina Chiara Garassino, Marcello Tiseo Lung Cancer, 2020
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, Francesco Passiglia, Francesca Mazzoni, Rossana Berardi, Claudia Proto, Fabiana Letizia Cecere, Sara Pilotto, Vieri Scotti, Sabrina Rossi, Alessandro Del Conte, Emanuele Vita, Chiara Bennati, Andrea Ardizzoni, Giulio Cerea, Maria Rita Migliorino, Elisa Sala, Andrea Camerini, Alessandra Bearz, Elisa De Carlo, Francesca Zanelli, Giorgia Guaitoli, Marina Chiara Garassino, Lucia Pia Ciccone, Giulia Sartori, Luca Toschi, Filippo Gustavo Dall’Olio, Lorenza Landi, Elio Gregory Pizzutilo, Gabriele Bartoli, Cinzia Baldessari, Silvia Novello, Emilio Bria, Diego Luigi Cortinovis, Giulio Rossi, Antonio Rossi, Giuseppe Luigi Banna, Roberta Camisa, Massimo Di Maio, Marcello Tiseo European Journal of Cancer, 2020
